Compound Profiles

Body Protection Compound-157

Synthetic peptide derived from human gastric juice. Extensive positive animal data for tendon, ligament and gut healing. No large-scale human trials.

GLP-1 Receptor Agonist

FDA-approved for weight management and type 2 diabetes. Robust clinical trial data. Compounded versions face an evolving regulatory landscape.

Growth Hormone Secretagogue Combination

Growth hormone secretagogue combination with synergistic effects. Documented human data for GH elevation. Furthest along in FDA reclassification.

Thymosin Beta-4 (synthetic fragment)

Synthetic Thymosin Beta-4. Frequently combined with BPC-157 for tissue repair through complementary mechanisms. Strongest human data is in ophthalmic applications.

Tα1 / Zadaxin (Immune Modulator)

Approved as Zadaxin in 35+ countries for hepatitis B and C. The strongest evidence base of any Category 2 peptide — 30+ trials, 11,000+ subjects. Frequently combined with BPC-157 for gut-focused immune support.

ACTH 4–10 Analog (Cognitive Nasal Peptide)

Russian-approved cognitive nasal peptide that modulates dopamine/serotonin and upregulates BDNF. The strongest evidence-to-risk ratio in the cognitive category, with the caveat that most research is in Russian.

Tuftsin Analog (Anxiolytic Nasal Peptide)

Nasal anxiolytic that modulates GABA without sedation, dependency, or tolerance. PCAC-referred September 2024 — further along in U.S. reclassification than Semax. Frequently paired with Semax.

Synthetic Hexapeptide (HGF/c-Met activator)

The most hyped and least proven cognitive peptide. Foundational research has been retracted, no human trials exist, and the “millions of times more potent than BDNF” claim traces back to compromised work. We cannot recommend it.

Spadin Analog (TREK-1 Channel Inhibitor)

Early-stage spadin analog targeting TREK-1 channels for mood and cognition. Almost entirely preclinical with minimal published data. Included for completeness.